Dr Amol Akhade· @SuyogCancer · X·· 2 天前评分90
正文 · 机器翻译
可能是 Trastuzumab deruxtecan 的首个阴性试验。Talent 试验。适用于早期 HR 阳性、Her2 低表达 EBC @myESMO #esmo26 @OncoAlert
2739 浏览 · 30 赞 · 8 转发 · 1 回复
会议摘要
LBA23按 Proffered paper 1: Breast cancer, early and advanced stage 对上
Final results of TALENT: A neoadjuvant trial of T-DXd with or without anastrozole, or in sequence with chemotherapy for HER2-low, HR+ early-stage breast cancer
https://esmocongress.esmo.org帖内回复
- Santhosh Ambika@RenoHemonc
@SuyogCancer @myESMO @OncoAlert Neoadj single agent TDxd was not impressive even in Her2+
来源：Dr Amol Akhade · x.com